Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 98Leukemia, Myeloid, Acute 95Lymphoma, Non-Hodgkin 93Multiple Myeloma 92Leukemia 91Lymphoma, Large B-Cell, Diffuse 90Lymphoma 90Leukemia, Lymphocytic, Chronic, B-Cell 89Lymphoma, Follicular 84Hodgkin Disease 84Lymphoma, Large-Cell, Immunoblastic 75Lymphoma, Mantle-Cell 74Burkitt Lymphoma 67Myelodysplastic Syndromes 64Lymphoma, B-Cell, Marginal Zone 60Leukemia, Myeloid, Chronic-Phase 55Leukemia, Myeloid, Accelerated Phase 55Congenital Abnormalities 51Neoplasms, Plasma Cell 49Myeloproliferative Disorders 49Blast Crisis 44Leukemia, Myelomonocytic, Chronic 42Waldenstrom Macroglobulinemia 41Recurrence 37Primary Myelofibrosis 32Lymphoma, T-Cell, Cutaneous 32Anemia, Refractory, with Excess of Blasts 29Sezary Syndrome 28Mycosis Fungoides 28Breast Neoplasms 28

Interventions

Amifostine 12Cisplatin 10Radiotherapy 8Etoposide 8Cyclophosphamide 5Paclitaxel 4Filgrastim 4Gemcitabine 3Cytarabine 3Carboplatin 3denileukin diftitox 2apatinib 2Vincristine 2Pyridoxine 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2Doxorubicin 2Dexamethasone 2Chemotherapy, Adjuvant 2Bleomycin 2uridine triacetate 1sargramostim 1peginterferon alfa-2b 1pegfilgrastim 1pegaspargase 1eribulin 1camrelizumab 1Vitamin E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00003068 2013-01-31

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡